{"denoms":[{"counts":[{"groupId":"BG000","value":"46"}],"units":"Participants"}],"groups":[{"description":"Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nNivolumab 360 mg: Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months\n\nPaclitaxel 200mg/m2: Paclitaxel 200mg/m2 IV Q3W\n\nCarboplatin AUC 6: Carboplatin AUC 6 IV Q3W","id":"BG000","title":"Arm 1"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.9","value":"63.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"34"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"46"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"46"}]}],"title":"Spain"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"}],"title":"ECOG 0"},{"measurements":[{"groupId":"BG000","value":"21"}],"title":"ECOG 1"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"ECOG 2"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"ECOG 3"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"ECOG 4"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"ECOG 5"}]}],"description":"ECOG Performance Status Scale: It describes a patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability\n\nGRADES:\n\nECOG 0: Fully active. ECOG 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature ECOG 2: Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours ECOG 3: Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours ECOG 4: Completely disabled ECOG 5: Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status Scale","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"}],"title":"Former smoker (≥ 1 year)"},{"measurements":[{"groupId":"BG000","value":"21"}],"title":"Current smoker"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Never smoker"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Cigarette Smoking History","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}],"title":"Adenocarcinoma"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Squamous"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"NOS/Undifferenciated"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}],"title":"T1N2M0"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"T2N1M0"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"T2N2M0"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"T3N1M0"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"T3N2M0"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"T4N0M0"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"T1N1M0"}]}],"description":"8th ed.TNM for Lung Cancer Primary tumor (T) T0 means there is no evidence of a tumor T1-T4 describe the size \\& location of the tumor on a scale of 1 to 4. A larger tumor or a tumor that has grown deeper into nearby tissue will get a higher number Distant metastasis (M) M0:Cancer has not spread to other parts of the body M1:Cancer has spread to other parts of the body Regional lymph nodes (N) N1: Metastasis in ipsilateral peribronchial or ipsilateral hilar lymph \\& intrapulmonary nodes N2:Metastasis in ipsilateral mediastinal or subcarinal lymph node N3:Metastasis in contralateral node","paramType":"COUNT_OF_PARTICIPANTS","title":"Tumor node, metastasis staging classification","unitOfMeasure":"Participants"}]}